Worsening of psychosis in schizophrenia is longitudinally associated with tardive dyskinesia in the European Schizophrenia Outpatient Health Outcomes study

Comprehensive Psychiatry
Diederik E TenbackSOHO Study Group

Abstract

The objective of the study was to examine if worsening of psychosis predicts the emergence of tardive dyskinesia (TD). Global measures of TD and Clinical Global Impression (CGI) overall symptom severity score were rated in 4 assessments in 12 months. In a risk set free of TD at baseline, associations between TD onset and change in CGI scores were assessed using Cox proportional hazard regression. A total of 8,620 patients yielded 23,565 follow-up observations, 8.8% of which represented a worsening in CGI overall symptom severity relative to the previous observation, yielding an incidence of TD of 5.2%, compared with 2.7% in observations without worsening of psychopathology (rate ratio, 1.9; 95% confidence interval, 1.3-2.7). Incidence of TD was longitudinally associated with a worsening of the CGI overall symptom severity in the months preceding TD onset (adjusted hazard ratio over 6 levels of CGI score, 1.3; 95% confidence interval, 1.1-1.4). Worsening in overall psychopathology in schizophrenia is longitudinally associated with the emergence of TD as measured by CGI overall symptom severity.

References

Nov 1, 1978·The American Journal of Psychiatry·G ChouinardL Annable
Jan 1, 1979·The American Journal of Psychiatry·G ChouinardJ N Nestoros
Oct 1, 1994·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jeffrey A LiebermanJohn M Kane
Dec 1, 1993·Schizophrenia Research·A ZaretskyX Fornazzari
May 1, 1994·The British Journal of Psychiatry : the Journal of Mental Science·P J DukeT R Barnes
Apr 1, 1996·Archives of General Psychiatry·Miranda H ChakosJeffrey A Lieberman
Jan 1, 1996·Acta Psychiatrica Scandinavica. Supplementum·L C Kopala
Apr 29, 1998·Journal of Clinical Psychopharmacology·R M Murray, Jim van Os
Feb 13, 2003·Acta Psychiatrica Scandinavica·J M HaroSOHO Study Group
Jun 11, 2003·Archives of General Psychiatry·John M DavisIra D Glick
Jun 26, 2003·The Journal of Clinical Psychiatry·Scott W Woods
Nov 25, 2003·The Journal of Clinical Psychiatry·Piet P OosthuizenN Keyter
Sep 24, 2005·International Journal of Methods in Psychiatric Research·Michael Höfler
Feb 17, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Diederik E TenbackSOHO Study Group

Citations

Oct 1, 2013·Epidemiology and Psychiatric Sciences·P R BakkerJim van Os
Sep 8, 2010·The Journal of Clinical Psychiatry·Stanley N CaroffCATIE Investigators
Nov 3, 2010·L'Encéphale·C DemilyGuy Chouinard
Sep 1, 2015·Psychiatry Research·Sebastian Walther
Nov 3, 2016·The British Journal of Psychiatry : the Journal of Mental Science·Robin M MurrayDavid Taylor
Jun 3, 2009·Journal of Psychopharmacology·Diederik E TenbackJim van Os
Apr 25, 2018·International Journal of Clinical Practice·Jan Volavka, Jan Vevera
Apr 14, 2015·The Cochrane Database of Systematic Reviews·Adegoke Oloruntoba AdelufosiTunde Massey-Ferguson Ojo

Related Concepts

Urgent Care
Dyskinesia, Medication-Induced
Schizophreniform Disorders
Schizophrenia
Severity of Illness Index
Antipsychotic Effect

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here